Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | PAM | P19021 | 2/20 | 0.30 |
| ▸ | FAAH | O00519 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL7220949 | 0.96 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18104018 | 0.96 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL168910 | 0.96 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL560522 | 0.96 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL3191369 | 0.96 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18104054 | 0.94 | MEN1 (0.47) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL821391 | 0.91 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL739576 | 0.90 | MEN1 (0.46) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL215134 | 0.86 | ATM (0.47) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL6697326 | 0.86 | MEN1 (0.49) | MEN1MAPTKMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532123-B1 | PROCESS FOR PREPARING 5-(1, 3-OXAZOL-2-YL) BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN CO LLC (US) | 2007-08-15 | — | — | EP | disclosed |
| CN-1324017-C | Process for preparing 5-(1, 3-oxazol-2-yl) benzoic acid derivatives | PHARMACIA & UPJOHN CO LLC (US) | 2007-07-04 | — | — | CN | disclosed |
| US-20070105921-A1 | Process for Preparing Oxazole Intermediates | PHARMACIA & UPJOHN COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-7115747-B2 | Process for preparing oxazole intermediates | PHARMACIA & UPJOHN COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| CN-1662510-A | Process for the preparation of 5- (1, 3-oxazol-2-yl) benzoic acid derivatives | PHARMACIA & UPJOHN CO LLC (US) | 2005-08-31 | — | — | CN | disclosed |
| EP-1532123-A1 | PROCESS FOR PREPARING 5-(1, 3-OXAZOL-2-YL) BENZOIC ACID DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040063965-A1 | Process for preparing oxazole intermediates | PHARMACEIA & UPJOHN | 2004-04-01 | — | — | US | disclosed |
| WO-2004000821-A1 | PROCESS FOR PREPARING 5-(1, 3-OXAZOL-2-YL) BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063965-A1 | Process for preparing oxazole intermediates | PSEN1, SOD1, OXA1L | MEN1 2001/4885MAPT 101/4885KMT2A 2663/4885 |
| US-20070105921-A1 | Process for Preparing Oxazole Intermediates | OXA1L, SOD1, PSEN1 | MEN1 1653/4885MAPT 204/4885KMT2A 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.